Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 105

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 105
---
 means afford only limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. For example:

| ● | others may be able to make                                                                                                           
 product candidates or develop a platform similar to, or better than, ours in a way that is not covered by the claims of our licensed 
 or owned patents;                                                                                                                    |

| ● | others may be able to make                                                                                                            
 compounds that are similar to our product candidates but that are not covered by the claims of patents we own or that are licensed to 
 us;                                                                                                                                   |

| ● | we or our prospective licensors                                                                                                        
 or future collaborators might not have been the first to make the inventions covered by any pending patent applications issued patents 
 that we own or license;                                                                                                                |

| ● | we or our prospective licensors                                                                                                                
 or future collaborators might not have been (or may not be in the future) the first to file patent applications for certain of our inventions; |

| ● | others may independently develop                                                                                              
 similar or alternative technologies or duplicate any of our technologies without infringing our intellectual property rights; |

| ● | our pending patent applications 
 may not lead to issued patents; |

| ● | issued patents that we own                                                                                    
 or license may be held invalid or unenforceable as a result of legal challenges by our competitors or others; |

| ● | our competitors might conduct                                                                                                       
 R&D activities in countries where we do not have patent rights and then use the information learned from such activities to develop 
 competitive products for sale in our major commercial markets;                                                                      |

| ● | any patents that we obtain,                                                                                                          
 or are licensed to us, may not provide us with any competitive advantages or protection against competitors, or may be challenged by 
 third parties;                                                                                                                       |

| ● | we cannot predict the scope                                                                                                                   
 of protection of any patent issuing based on our patent applications, including whether the patent applications that we own or may in-license 
 in the future will result in issued patents with claims that cover our product candidates or uses thereof in the United States or in          
 other foreign countries;                                                                                                                      |

55

| ● | if we attempt to enforce our                                                                
 patents, a court may hold that our patents are not invalid, unenforceable or not infringed; |

| ● | we may not develop additional                 
 proprietary technologies that are patentable; |

| ● | we may need to initiate litigation                                                                                    
 or administrative proceedings to enforce and/or defend our patent rights which will be costly whether we win